This table presents recent patent oppositions filed by Allergan Pharmaceuticals International Limited against its competitors. It outlines key details of each case, including the patent title, filing date and the applicant. This information provides insights into the competitive landscape and highlights active disputes over patent grant within the industry.

Patent NumberTitleApplicantOpposition Date
EP2800811Methods And Compositions For Rna-Directed Target Dna Modification And For Rna-Directed Modulation Of TranscriptionCHARPENTIER, EMMANUELLEFeb 11, 2018

The following table provides an overview of the latest patents of Allergan Pharmaceuticals International Limited that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP3509559Jul 19, 2023Injectable Gels Comprising Cross-Linked Hyaluronic Acid And Hydroxyapatite, And Methods Of Manufacturing Thereof1
EP3024479Feb 8, 2023High Potency Pancreatin Pharmaceutical Compositions1
EP3003360Oct 7, 2020High Potency Pancreatin Pharmaceutical Compositions1
EP2922532Mar 6, 20195-Aminosalicylic Acid Capsule Formulation1
EP2818160Nov 8, 2017Enteric Coated, Low-Strength Pancrelipase Formulations1